Overview
Dr. Channing J. Paller is a medical oncologist at Sibley Memorial Hospital and a professor of oncology at the Johns Hopkins University School of Medicine. She practices out of the Prostate Cancer Multidisciplinary Clinic at Sibley Memorial Hospital in Washington, D.C., and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD. Dr. Paller has expertise in prostate, bladder, kidney, and testicular cancer. Dr. Paller earned her medical degree from Harvard Medical School and completed a residency in internal medicine, followed by a fellowship in hematology and oncology at Johns Hopkins University School of Medicine. In addition, Dr. Paller completed a rotation with the chief of the Investigational Drug Branch at the National Cancer Institute (NCI) Cancer Therapy Evaluation Program and a rotation with the associate director for regulatory science in the Office of Oncology Drug Products at the Food and Drug Administration. She also completed rotations at the Weizmann Institute of Israel’s Department of Biological Regulation and McCord Hospital in South Africa, where she participated in the Harvard AIDS project. In 2016, Dr. Paller was one of only five oncologists awarded the NCI Mentored Patient-Oriented Research Career Development Award. In 2015, she received the 2015 Passano Clinician Scientist Award for early-stage research that is already making a contribution to science. Earlier in her career, she was selected for both a 2011-2012 Young Investigator Award by the American Society of Clinical Oncology and for the 2011-12 Eastern Cooperative Oncology Group Paul Carbone Award. Dr. Paller is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Paller’s research focuses on evaluating new therapies for prostate cancer, particularly combination therapies that engage the immune system. She is the principal investigator on two multi-site clinical trials and was the first author on the NCI Investigational Drug Steering Committee publication, “Consensus Recommendations on the Phase I Combination Clinical Trials of the Clinical Trial Design Task Force.” Dr. Paller was the chair for the oral abstract session on genitourinary cancer at the 2015 Annual Meeting of the American Society of Clinical Oncology and she is currently funded by an NCI immunotherapy grant to look at combination therapies that link standard of care therapy with inhibition of transforming growth factor beta in prostate cancer. She is also opening trials of vitamin C with chemotherapy in prostate cancer and of mistletoe in all solid tumors.
Dr. Paller is rated as an Elite provider by MediFind in Hormone Replacement Therapy (HRT). Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Hormone Replacement Therapy (HRT), and Prostatectomy.
Her clinical research consists of co-authoring 134 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 7 articles and participated in 1 clinical trial in the study of Hormone Replacement Therapy (HRT).
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Building B, Washington, DC 20016
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
13 Clinical Trials
Skip Viragh Outpatient Cancer Center
Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Urology at the Johns Hopkins University School of Medicine and Director of the Genitourinary Oncology Division for the Johns Hopkins Kimmel Cancer Center. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer. Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine. His research interests include prostate cancer, bipolar androgen therapy, clinical trials and targeted drug development. Dr. Denmeade has published over 200 papers in the area of prostate cancer research. He has received extensive funding from the NIH, the Department of Defense Prostate Cancer Research Fund and the Prostate Cancer Foundation. He is the Editor-in-Chief of the medical journal The Prostate. Dr. Denmeade is rated as a Distinguished provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy.
Sibley Memorial Hospital
Dr. Mark Markowski is a medical oncologist at the Kimmel Cancer Center at Sibley Memorial Hospital, as well as an Associate Professor in the Department of Oncology at Johns Hopkins University School of Medicine. Dr. Markowski participates in multidisciplinary clinics at Sibley and The Johns Hopkins Hospital, and sees patients in the genitourinary clinics of both hospitals. Dr. Markowski treats numerous types of cancers, with a specialty in prostate and kidney cancers. Dr. Markowski earned his medical degree and Ph.D. in tumor biology at Georgetown University School of Medicine. He completed a residency in internal medicine at Columbia University, followed by a medical oncology fellowship at Johns Hopkins Hospital. Dr. Markowski previously served as a research associate at the Lombardi Comprehensive Cancer Center at Georgetown University. His research interests focus on early phase drug development for prostate cancer, as well a non-castrating therapies for patients with metastatic disease. Dr. Markowski is currently conducting research with funding from a Department of Defense Prostate Cancer Research Program Award and a Challenge Award from the Prostate Cancer Foundation, which focuses on new treatment strategies for prostate cancer patients. Dr. Markowski is rated as a Distinguished provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Wilms Tumor 2, Hormone Replacement Therapy (HRT), and Prostatectomy.
Mario Eisenberger is an Oncologist in Baltimore, Maryland. Dr. Eisenberger is rated as a Distinguished provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Familial Prostate Cancer, Hormone Replacement Therapy (HRT), and Prostatectomy.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Hormone Replacement Therapy (HRT)
- Prostate CancerDr. Paller isElite. Learn about Prostate Cancer.
- Distinguished
- Familial Prostate CancerDr. Paller isDistinguished. Learn about Familial Prostate Cancer.
- Advanced
- Muscle Invasive Bladder CancerDr. Paller isAdvanced. Learn about Muscle Invasive Bladder Cancer.
- Penile CancerDr. Paller isAdvanced. Learn about Penile Cancer.
- ProstatectomyDr. Paller isAdvanced. Learn about Prostatectomy.
- Renal Cell Carcinoma (RCC)Dr. Paller isAdvanced. Learn about Renal Cell Carcinoma (RCC).
- Experienced
- Adrenal Insufficiency PediatricDr. Paller isExperienced. Learn about Adrenal Insufficiency Pediatric.
- Adult Soft Tissue SarcomaDr. Paller isExperienced. Learn about Adult Soft Tissue Sarcoma.
- Bladder CancerDr. Paller isExperienced. Learn about Bladder Cancer.
- Bone TumorDr. Paller isExperienced. Learn about Bone Tumor.
- Breast CancerDr. Paller isExperienced. Learn about Breast Cancer.
- Chromophobe Renal Cell CarcinomaDr. Paller isExperienced. Learn about Chromophobe Renal Cell Carcinoma.